Lv1
70 积分 2025-03-05 加入
Teclistamab as monotherapy in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy
16天前
已关闭
Teclistamab – myélome multiple en rechute ou réfractaire après au moins trois traitements antérieurs
16天前
已关闭
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies
17天前
已完结
Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting
17天前
已完结
Administration of teclistamab in four patients with multiple myeloma requiring hemodialysis
17天前
已完结
Safety outcomes of teclistamab accelerated dose escalation
17天前
已完结
Incidence of Acute Kidney Injury in Relapsed and Refractory Multiple Myeloma treated with Teclistamab versus CAR T-cells
17天前
已完结
Teclistamab for relapsed refractory multiple myeloma patients on dialysis
17天前
已完结
Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting
17天前
已完结
Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study
1个月前
已关闭
皖公网安备34019202002308
